To comprehensively profile serum carboxyl-containing metabolites (CCMs) in pediatric patients with allergic rhinitis (AR), asthma, and combined allergic rhinitis and asthma syndrome (CARAS) to identify common and disease-specific metabolic alterations, particularly focusing on immune dysregulation and gut dysbiosis.
Key Findings:
Identified 100 differentially expressed metabolites common across AR, asthma, and CARAS, suggesting shared metabolic pathways.
Found 23 unique metabolites for AR, 17 for asthma, and 31 for CARAS, indicating distinct metabolic profiles that could inform targeted therapies.
AR exhibited localized amino acid perturbations, asthma showed systemic lipid remodeling, and CARAS displayed a combination of both, highlighting the complexity of these conditions.
Interpretation:
The study reveals shared metabolic disturbances in allergic airway diseases, indicating immune dysregulation and potential gut dysbiosis, while also highlighting distinct metabolic profiles for each condition, which could guide future research and clinical approaches.
Limitations:
Retrospective design may limit causal inferences and introduce selection bias.
Sample size for each group may affect the robustness of findings, necessitating further validation in larger cohorts.
Conclusion:
The findings provide novel insights into the metabolic mechanisms underlying allergic airway diseases, potentially aiding in the development of biomarkers for diagnosis and treatment.
